Centennial, Colo. — March 1, 2016 — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, announced today the launch of ProChondrix® Cartilage Restoration Matrix, a cellular 3D fresh cartilage allograft helping to provide the necessary components for cartilage regeneration.
This patented, next generation of cartilage therapy is designed to match biomechanical and biochemical properties of normal hyaline cartilage, restore a smooth articular cartilage surface and relieve patient symptoms and improve function.
“One of the most important ways we honor tissue donors is through our commitment to innovation,” said Thomas Cycyota, AlloSource president and CEO. “ProChondrix provides the opportunity to both maximize the donor’s gift, while also helping recipients get their mobility back.”
ProChondrix offers an extracellular matrix to help support a structure for cellular migration and adhesion, while preserving growth factors. The presence of native growth factors helps maintain healthy cartilage and facilitate chondrocyte functionality. ProChondrix also contains viable chondrocytes that can aid in cartilage repair by generating extracellular matrix proteins to help promote chondrogenesis.
“We discovered without the regeneration of new cartilage, many patients who had a successful microfracture surgery required a partial or full knee replacement in as few as five years’ time,” said Dr. Vishal Mehta, orthopedic surgeon at Fox Valley Orthopedics. “ProChondrix works by enhancing the success of a microfracture surgery and allowing the affected area to more naturally heal and rebuild strength.”
For more information on ProChondrix and presentations on early clinical results, please visit booth 2835 at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, March 2-4, 2016 in Orlando, Florida.